Rensselaer, NY – Scientific Director Selected for National Honor
Sally Temple has been elected to the National Academy of Medicine (NAM), a prestigious honor awarded in recognition of her pioneering scientific work and demonstrated record of service within her profession. The NAM chooses only 100 new national and international members each year from leaders in the fields of science, medicine and public health.
Announcing the 2022 selections, the Academy cited Dr. Temple’s discovery and novel characterization of neural stem cells present in the brain of adult mammals, including mice and humans. She has made significant contributions toward modeling and development of treatments for macular degeneration and neurodegenerative diseases of the brain. In addition, she has provided leadership within the International Society for Stem Cell Research (ISSCR) for more than 13 years, and serves in a voluntary capacity as a scientific advisor to numerous U.S.- and internationally-based organizations. She has published more than 100 journal articles related to neurobiology, biotechnology and equity in science.
Currently, Dr. Temple is the Scientific Director of Regenerative Research Foundation (RRF) which she co-founded in 2005, seeking to accelerate translation of scientific discoveries to improve lives for people afflicted by neurodegenerative diseases. Located in New York State’s Capital Region, RRF was the first independent stem cell research institute in the United States. RRF’s research activities are carried out by the Neural Stem Cell Institute which includes NeuraCell, a core facility that specializes in disseminating stem cell-derived products, brain organoids and methods developed at RRF to scientists around the world. In 2022, RRF and Luxa Biotechnology, LLC initiated their first clinical trial, a Phase 1/2a study to assess an adult stem cell replacement therapy for Age-related Macular Degeneration (AMD).
Read the full announcement from the National Academy of Medicine here.